SCHEMBL1090729

SCHEMBL1090729

COc1ccc(C(=O)N2CCCC(N3CCC(Nc4nccc(N5CCCCCC5)n4)C3)C2)cc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CDK12 Q9NYV4 10/20 0.53
CCNK O75909 9/20 0.53
ALDH1A1 P00352 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CCNA2 P20248 6/20 0.46
CDK2 P24941 6/20 0.46
CDK7 P50613 6/20 0.46
CCNH P51946 6/20 0.46
MNAT1 P51948 6/20 0.46
POLB P06746 2/20 0.46
CCNC P24863 1/20 0.45
CDK8 P49336 1/20 0.45
CXCR4 P61073 1/20 0.45
PDE2A O00408 1/20 0.44
PDE3A Q14432 1/20 0.44
MAPK10 P53779 2/20 0.44
PROKR1 Q8TCW9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1090264 0.97 CDK12 (0.54) CDK12CCNKALDH1A1SMN1; SMN2CCNA2
SCHEMBL1090615 0.96 CDK12 (0.54) CDK12CCNKALDH1A1SMN1; SMN2CCNA2
SCHEMBL1089141 0.92 CDK12 (0.48) CDK12CCNKALDH1A1SMN1; SMN2CCNA2
SCHEMBL1089125 0.91 CDK12 (0.55) CDK12CCNKCCNA2CDK2CDK7
SCHEMBL1091235 0.91 GFER (0.49) CDK12CCNKALDH1A1CCNCCDK8
SCHEMBL1090830 0.91 CDK12 (0.54) CDK12CCNKALDH1A1SMN1; SMN2CCNA2
SCHEMBL1090849 0.90 CDK12 (0.49) CDK12CCNKCCNA2CDK2CDK7
SCHEMBL1090175 0.89 CDK12 (0.51) CDK12CCNKALDH1A1SMN1; SMN2CCNA2
SCHEMBL1089893 0.89 CDK12 (0.53) CDK12CCNKALDH1A1CCNA2CDK2
SCHEMBL1089722 0.89 CXCR4 (0.55) CDK12CCNKALDH1A1CCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-06-21 US disclosed
US-8153625-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-04-10 US disclosed
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2010-09-02 US disclosed
US-7759336-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-20 US disclosed
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-19 US disclosed
EP-1571146-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 CDK12 2526/4885CCNK 793/4885ALDH1A1 916/4885
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof CXCR4, CXCL12, CXCR3 CDK12 2526/4885CCNK 793/4885ALDH1A1 916/4885
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 CDK12 2526/4885CCNK 793/4885ALDH1A1 916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.